Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Administrative backlog at public authority causes short-term delay in Tourette study

(Stockholm, 16 September, 2021.) An administrative backlog due to Covid-19 at The Capital Region of Denmark (Region Hovedstaden) is causing a delay of approx. 3 months to the initiation of Asarina Pharma’s phase IIa study in Tourette Syndrome. The study is now expected to start in December 2021 and be completed at the end of…

Full PDF

Asarina Pharma AB (publ) Q2 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, and the granting of our first US…

Full PDF

Asarina Pharma reports topline results in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today releases topline results from its Phase IIa study of Sepranolone for the treatment of menstrual migraine. While a 25% reduction in menstrual migraine days was achieved across the patient population, a statistically significant difference compared to placebo was not obtained for the study’s primary and secondary endpoints.…

Full PDF

Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling

(Stockholm, 8 June 2021.) The US Patent and Trademark Office has granted a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling. CEO Peter Nordkild: “The powerful neurosteroid Allopregnanolone (ALLO) seems to be the missing link in a raft of stress-related disorders, from Tourette to OCD, characterized by tics and…

Full PDF

Asarina Pharma obtains convertible loan for continued research on neurological conditions including Obsessive Compulsive Disorder

(Stockholm, 31 May 2021) Asarina Pharma AB (publ) has obtained a convertible loan of 5.3 MSEK from Östersjöstiftelsen (ÖSS), one of its key shareholders, for ongoing and upcoming R&D into neurological disorders including OCD (Obsessive Compulsive Disorder).

Full PDF